Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olanzapine vs Paliperidone Palmitate in First-Episode Schizophrenia
NCT02918825Completed
- Sponsor
- Peking University Huilongguan Hospital
- Start
- Sep 2016
- Primary completion
- Aug 2017
- Modality
- Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Randomised, single-blind trial of paliperidone palmitate in schizophrenia (2 arms), sponsored by Peking University Huilongguan Hospital. Primary endpoint: Positive and Negative Syndrome Scale at 12 weeks. Started Sep 2016; status: completed.
02
Drugs
paliperidone palmitate
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02918825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02918825.